The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Making weight loss injections available to all eligible individuals in the U.K. could yield an economic boost of 4.5 billion ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Amble Health's website states it is a platform connecting patients to licensed healthcare professionals online, who can ...

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

The boss of the drugs giant behind Ozempic has quit after falling behind in the global race to develop weight-loss medication ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual ...

Jorgensen, who has been CEO since 2017, will remain in the role until a new CEO has been appointed, Novo Nordisk said ...